Holen Sie sich die Stockscreener-App
3.13
23.39%
0.65
Schlusskurs vom Vortag:
$2.48
Offen:
$3.34
24-Stunden-Volumen:
17.08M
Relative Volume:
233.06
Marktkapitalisierung:
$28.61M
Einnahmen:
$2.09M
Nettoeinkommen (Verlust:
$-30.04M
KGV:
-0.9576
EPS:
-3.2685
Netto-Cashflow:
$-27.57M
1W Leistung:
+5.88%
1M Leistung:
-11.05%
6M Leistung:
-63.35%
1J Leistung:
-57.85%
1-Tages-Spanne:
$3.02
$3.37
1-Wochen-Bereich:
$2.13
$3.37
52-Wochen-Spanne:
$2.13
$13.13
Cervomed Inc Stock (CRVO) Company Profile
Firmenname
Cervomed Inc
Sektor
Branche
Telefon
(617) 744-4400
Adresse
20 PARK PLAZA, BOSTON
Compare CRVO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
3.09 | 22.96M | 2.09M | -30.04M | -27.57M | -3.2685 |
VRTX
Vertex Pharmaceuticals Inc
|
445.33 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
873.08 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.94 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.85 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-13 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-12-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-18 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-07-26 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cervomed Inc Aktie (CRVO) Neueste Nachrichten
CervoMed Inc. Files Form 8-K with SEC – Company Information, Address, and Common Stock Details - Minichart
Why did CRVO stock crash 22% in pre-market trading today? - MSN
CervoMed Posts Updated Investor Presentation and Business Overview - TipRanks
CervoMed director Joshua Boger acquires $2.99m in common stock By Investing.com - Investing.com India
Cervomed Insider Bought Shares Worth $3,000,000, According to a Recent SEC Filing - marketscreener.com
CervoMed (CRVO) major holder Boger discloses 19.99% ownership stake - Stock Titan
Boger family trusts boost CervoMed (CRVO) stake with 955K-unit private deal - Stock Titan
CervoMed (NASDAQ: CRVO) updates investor presentation for use in meetings - Stock Titan
CRVO: Advancing neflamapimod to phase III in DLB, with strategic partnership and strong clinical data - TradingView
CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - 富途牛牛
CervoMed Insiders Lose Out As Stock Sinks To US$2.45 - Yahoo Finance
CervoMed Inc. (CRVO) Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Progress ContinuesEPS Revision Trend - newsline.com
CervoMed Inc. (CRVO) Surges 8.44%: Testing Key Resistance at $2.56TWAP Entry - newsline.com
CervoMed Inc. (CRVO) Gains 8.4%: Support Holds as Stock Approaches Key ResistanceBearish Sentiment - newsline.com
CervoMed (CRVO) director Frank Zavrl receives grant of 8,150 stock options - Stock Titan
CervoMed (CRVO) awards 8,150 stock options to new board director - Stock Titan
CervoMed (CRVO) grants director David Quigley options on 8,150 shares - Stock Titan
[Form 4] CervoMed Inc. Insider Trading Activity - Stock Titan
CervoMed (CRVO) director receives options for 8,150 shares at $2.91 strike - Stock Titan
CervoMed (CRVO) director Sylvie Gregoire receives 8,150-share stock option award - Stock Titan
CervoMed (CRVO) director and 10% owner granted 8,150 stock options at $2.91 - Stock Titan
CervoMed (CRVO) director and CEO’s spouse granted 8,150 stock options - Stock Titan
CRVO Q1 2026 Earnings: Wider-Than-Expected Loss Amid Pre-Revenue Development PhaseEarnings Call Q&A - newsline.com
CervoMed (CRVO) Secures $10.5M from Private Placement - GuruFocus
CervoMed (CRVO) Secures $10.5 Million from Private Placement - GuruFocus
Why Did CRVO Stock Crash 22% In Pre-Market Trading Today? - Asianet Newsable
CervoMed stock falls 15% after $10.5M financing announced By Investing.com - Investing.com South Africa
CervoMed stock falls 15% after $10.5M financing announced - Investing.com
CervoMed Announces Private Placement to Advance Neurology Pipeline - TipRanks
CervoMed raises $10.5 million in private placement financing - Investing.com
CervoMed : Corporate Presentation (54c99e) - marketscreener.com
CervoMed raises $10.5 million in private placement financing By Investing.com - Investing.com Canada
CervoMed Secures $10.5M Private Placement of Units With Warrants; Up to $21.7M More Possible - TradingView
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies - The Manila Times
CervoMed (NASDAQ: CRVO) secures $10.5M financing to extend cash runway into 2027 - Stock Titan
CervoMed shareholders approve board elections and key proposals at annual meeting By Investing.com - Investing.com South Africa
CervoMed Shareholders Back Board, Pay and Incentive Plan - TipRanks
CervoMed shareholders approve board elections and key proposals at annual meeting - Investing.com
CervoMed (NASDAQ: CRVO) logs 67% turnout, backs 2026 proposals - Stock Titan
CRVO Q1 2026 Earnings: Wider-than-Expected Loss on No Revenue; Stock Slightly DownEarnings Decline Risk - newsline.com
CRVO Q1 2026 Earnings: EPS Misses Estimates as Clinical‑Stage Biotech Maintains R&D FocusPositive Surprise Momentum - newsline.com
CervoMed Inc. (CRVO) Edges Lower as Stock Tests Support Near $3.00Trend Following Picks - The Legal Advocate
H.C. Wainwright Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $25 - Moomoo
CervoMed Inc. (CRVO) Hovers Near Key Support After Marginal DeclineHedge Fund Exposure - newsline.com
CRVO Q1 2026 Earnings: EPS Misses EstimatesEarnings Revision Report - The Legal Advocate
CRVO Q1 2026 Earnings: EPS Miss Reflects Continued Clinical InvestmentReal Trader Network - Newser
CervoMed Stock Slides Into Long Weekend as CRVO’s Cash Clock Tests Phase 3 Hopes - Bez Kabli
CervoMed Inc. (CRVO) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock DeclineNet Profit Margin - Newser
CRVO Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Clinical Stage Company Reports No RevenueTrough Earnings Signal - The Legal Advocate
Finanzdaten der Cervomed Inc-Aktie (CRVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):